Katharine Louise Lewis

19PUBLICATIONS
141CO-AUTHORS
Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersSolid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Jun 11, 2026
High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

|Feb 05, 2026
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter transformation.

Katharine Louise Lewis, Sarit E Assouline, Ross Ian Baker

|Dec 07, 2025
Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Jennifer A Woyach, Lugui Qiu, Sebastian Grosicki

|May 06, 2025
An international real-world study of primary vitreoretinal lymphoma from the Australasian lymphoma alliance and collaborators.

Catherine Tang, Catriona Downie, Mandeep S Sagoo

|Feb 13, 2025
BTK Is the Target That Keeps on Giving: A Review of BTK-Degrader Drug Development, Clinical Data, and Future Directions in CLL.

Ross T Salvaris, Jamie Brennan, Katharine L Lewis

|Sep 27, 2024
In the SARS-CoV-2 era, do we need to be afraid of obinutuzumab?

Joleen Choy, Katharine L Lewis

Pageof 4

Frequent Collaborators

14 joint publications

Chan Yoon Cheah

5 joint publications

Matthew Ku

4 joint publications

Nada Hamad

4 joint publications

Diego Villa